Hanmi Secures Export Deal with Mexican Partner Sanfer for GLP-1 Obesity Drug and More

2026-01-28 - 04:33

Hanmi Signs Exclusive Partnership with New Mexican Partner Laboratorios Sanfer, Covering Efpeglenatide and Diabetes Treatments SEOUL, South Korea, Jan. 28, 2026 /PRNewswire/ — Hanmi is accelerating its global market entry with efpeglenatide, Korea’s first domestically developed GLP-1 class obesity and metabolic disease treatment. Hanmi Pharmaceutical, the core operating company of Hanmi Science, announced on January